ATE403654T1 - Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren - Google Patents

Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren

Info

Publication number
ATE403654T1
ATE403654T1 AT04779219T AT04779219T ATE403654T1 AT E403654 T1 ATE403654 T1 AT E403654T1 AT 04779219 T AT04779219 T AT 04779219T AT 04779219 T AT04779219 T AT 04779219T AT E403654 T1 ATE403654 T1 AT E403654T1
Authority
AT
Austria
Prior art keywords
benzothiazole
benzimidazole
benzoxazole derivatives
lta4h modulators
lta4h
Prior art date
Application number
AT04779219T
Other languages
English (en)
Inventor
Frank Axe
Scott Bembenek
Christopher Butler
James Edwards
Anne Fourie
Cheryl Grice
Brad Savall
Kevin Tays
Jianmei Wei
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE403654T1 publication Critical patent/ATE403654T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Materials Engineering (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04779219T 2003-07-28 2004-07-27 Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren ATE403654T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49071003P 2003-07-28 2003-07-28

Publications (1)

Publication Number Publication Date
ATE403654T1 true ATE403654T1 (de) 2008-08-15

Family

ID=34115427

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04779219T ATE403654T1 (de) 2003-07-28 2004-07-27 Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren
AT04779375T ATE405562T1 (de) 2003-07-28 2004-07-27 Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04779375T ATE405562T1 (de) 2003-07-28 2004-07-27 Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren

Country Status (29)

Country Link
US (2) US20050043379A1 (de)
EP (2) EP1660491B1 (de)
JP (2) JP4726238B2 (de)
KR (2) KR20060054408A (de)
CN (2) CN1856490A (de)
AR (2) AR045730A1 (de)
AT (2) ATE403654T1 (de)
AU (2) AU2004261610B2 (de)
BR (2) BRPI0413072A (de)
CA (2) CA2534228A1 (de)
CY (1) CY1108560T1 (de)
DE (2) DE602004016002D1 (de)
DK (2) DK1660491T3 (de)
ES (2) ES2313079T3 (de)
HK (2) HK1092790A1 (de)
HR (2) HRP20060041B1 (de)
IL (1) IL173372A (de)
MY (1) MY145080A (de)
NO (2) NO20060771L (de)
NZ (2) NZ544970A (de)
PL (2) PL1660492T3 (de)
PT (2) PT1660491E (de)
RU (2) RU2359970C2 (de)
SG (2) SG130192A1 (de)
SI (2) SI1660491T1 (de)
TW (2) TW200520756A (de)
UA (2) UA87986C2 (de)
WO (2) WO2005012296A1 (de)
ZA (2) ZA200601716B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1856490A (zh) * 2003-07-28 2006-11-01 詹森药业有限公司 苯并咪唑、苯并噻唑和苯并噁唑衍生物及其作为lta4h调节剂的应用
KR20080003385A (ko) * 2005-03-31 2008-01-07 얀센 파마슈티카 엔.브이. 페닐 및 피리딜 ｌｔａ４ｈ 조절제
RS52715B (en) 2005-04-13 2013-08-30 Astex Therapeutics Limited HYDROXYBENZAMIDE DERIVATIVES AND THEIR APPLICATIONS AS HSP90 INHIBITORS
EP1717235A3 (de) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidine und -pyrrolidine und ihre Verwendung als Liganden für den Histamin H3-Rezeptor
KR101047221B1 (ko) * 2005-09-02 2011-07-06 에프. 호프만-라 로슈 아게 벤조옥사졸, 옥사졸로피리딘, 벤조싸이아졸 및싸이아졸로피리딘 유도체
CN101312948B (zh) * 2005-09-21 2015-01-14 解码遗传Ehf公司 用于治疗炎症的lta4h的二芳基取代杂环抑制剂
WO2007073405A1 (en) * 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
CA2634701C (en) * 2005-12-21 2014-07-29 Decode Genetics Ehf Biaryl substituted nitrogen containing heterocycle inhibitors of lta4h for treating inflammation
WO2007078335A2 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
LT1976828T (lt) * 2005-12-29 2017-04-25 Celtaxsys, Inc. Diamino dariniai, kaip leukotrieno a4 hidrolazės inhibitoriai
US8354434B2 (en) * 2006-01-30 2013-01-15 Purdue Pharma L.P. Cyclourea compounds as calcium channel blockers
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US7951829B2 (en) * 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
PL2044020T3 (pl) * 2006-06-16 2011-09-30 H Lundbeck As Krystaliczne postaci 4-[2-(4-metylofenylosulfanylo)-fenylo]piperydyny z równoczesnym hamowaniem wychwytu zwrotnego serotoniny i norepinefryny do leczenia bólu neuropatycznego
WO2008019302A1 (en) * 2006-08-04 2008-02-14 Decode Genetics Ehf Pyrazolylphenyl and pyrrolylphenyl inhibitors of lta4h for treating inflammation
US7989480B2 (en) 2006-08-04 2011-08-02 Decode Genetics Ehf Aryl amino acid derivatives as inhibitors for treating inflammation
WO2008019284A1 (en) * 2006-08-04 2008-02-14 Decode Genetics Ehf Phenoxymethylalkyne inhibitors of lta4h for treating inflammation
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
EP2073802A1 (de) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmazeutische kombinationen
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
CL2008000468A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Uso de compuestos derivados de heterociclos, inhibidores de leucotrina a4 hidrolasa (lta4h), utiles para tratar o prevenir la dermatitis, acne, infarto al miocardio, dolor, picazon, gingivitis, cancer, artritis, entre otras.
PL2134704T3 (pl) * 2007-03-08 2011-03-31 Irm Llc Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
US20100100012A1 (en) * 2007-03-30 2010-04-22 Yoshihiro Matsumura Activity intensity measurement device
TW200932236A (en) * 2007-10-31 2009-08-01 Janssen Pharmaceutica Nv Aryl-substituted bridged diamines as modulators of leukotriene A4 hydrolase
AU2008322595B2 (en) * 2007-11-16 2014-01-30 Abbvie Inc. Method of treating arthritis
US7939527B2 (en) 2008-04-11 2011-05-10 Janssen Pharmaceutica Nv Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
WO2009134750A1 (en) 2008-04-28 2009-11-05 Janssen Pharmaceutica Nv Benzoimidazoles as prolyl hydroxylase inhibitors
US8399465B2 (en) * 2009-05-14 2013-03-19 Janssen Pharmaceutica Nv Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase
CN102442961A (zh) * 2010-11-10 2012-05-09 江苏德峰药业有限公司 1-甲基四氮唑的生产方法
CN102442962A (zh) * 2010-11-10 2012-05-09 江苏德峰药业有限公司 1-烷基四氮唑的生产方法
ES2689481T3 (es) 2011-10-25 2018-11-14 Janssen Pharmaceutica Nv Formulaciones de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
ES2864862T3 (es) 2013-03-12 2021-10-14 Celltaxis Llc Métodos de inhibición de la leucotrieno A4 hidrolasa
EP2970309A4 (de) 2013-03-14 2016-11-09 Celtaxsys Inc Inhibitoren der leukotrien-a4-hydrolase
AU2014239585B2 (en) * 2013-03-14 2019-04-04 Celtaxsys, Inc. Inhibitors of leukotriene A4 hydrolase
AU2014240042C1 (en) 2013-03-14 2019-09-05 Celltaxis, Llc Inhibitors of leukotriene A4 hydrolase
LT3083562T (lt) * 2013-12-17 2018-01-10 Eli Lilly & Company Fenoksietilo cikliniai amino dariniai ir jų aktyvumas kaip ep4 receptoriaus moduliatorių
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
WO2016100823A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
WO2016200851A1 (en) 2015-06-09 2016-12-15 Abbvie Inc. Nuclear receptor modulators
WO2018114879A1 (en) 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag Method for in vitro glycoengineering of antibodies
CN107663192B (zh) * 2017-11-03 2019-05-10 梯尔希（南京）药物研发有限公司 一种雷贝拉唑杂质的制备方法
US10898484B2 (en) 2018-05-31 2021-01-26 Celltaxis, Llc Method of reducing pulmonary exacerbations in respiratory disease patients
JP2022517316A (ja) * 2019-01-11 2022-03-08 ネイジス ファーマシューティカルズ インコーポレイテッド ロイコトリエン合成阻害剤
CN110026557B (zh) * 2019-05-28 2021-08-27 南方科技大学 一种混合固体颗粒重熔的直写装置及成型方法
US20230416202A1 (en) * 2020-11-19 2023-12-28 Telo Therapeutics, Inc. Small Molecule Compounds and Compositions
CN113683491A (zh) * 2021-09-01 2021-11-23 王传良 一种4-(2-溴乙基)苯酚的制备方法
CN113735798B (zh) * 2021-09-27 2022-07-12 安徽美致诚药业有限公司 一种盐酸罗沙替丁醋酸酯的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873346A (en) * 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
CA1319144C (en) * 1986-11-14 1993-06-15 Quirico Branca Tetrahydronaphthalene derivatives
IT1240598B (it) * 1990-03-13 1993-12-17 Mini Ricerca Scient Tecnolog Derivati amminici ad azione antifungina
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5925654A (en) * 1997-03-12 1999-07-20 G.D. Searle & Co. LTA4 , hydrolase inhibitors
EP1062216A1 (de) * 1998-02-25 2000-12-27 Genetics Institute, Inc. Phospholipase a2 inhibitoren
US6514964B1 (en) * 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US20040110757A1 (en) * 2002-03-21 2004-06-10 Thomas Arrhenius Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
CN1856490A (zh) * 2003-07-28 2006-11-01 詹森药业有限公司 苯并咪唑、苯并噻唑和苯并噁唑衍生物及其作为lta4h调节剂的应用
US7541466B2 (en) * 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
JP4991693B2 (ja) * 2005-03-16 2012-08-01 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 呼吸器疾患の治療のための抗コリン作用薬及びロイコトリエン受容体アンタゴニストの組み合わせ剤
CL2008000468A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Uso de compuestos derivados de heterociclos, inhibidores de leucotrina a4 hidrolasa (lta4h), utiles para tratar o prevenir la dermatitis, acne, infarto al miocardio, dolor, picazon, gingivitis, cancer, artritis, entre otras.

Also Published As

Publication number Publication date
ZA200601720B (en) 2007-11-28
EP1660491B1 (de) 2008-08-06
HRP20060041B1 (hr) 2014-06-06
CN100591679C (zh) 2010-02-24
KR20060057593A (ko) 2006-05-26
EP1660492A1 (de) 2006-05-31
SG129449A1 (en) 2007-02-26
EP1660492B1 (de) 2008-08-20
DE602004015620D1 (de) 2008-09-18
NZ544938A (en) 2009-05-31
IL173372A0 (en) 2006-06-11
US20050043378A1 (en) 2005-02-24
EP1660491A1 (de) 2006-05-31
HRP20060039A2 (en) 2006-08-31
AU2004261610A1 (en) 2005-02-10
DK1660492T3 (da) 2008-11-03
SG130192A1 (en) 2007-03-20
TW200520756A (en) 2005-07-01
JP2007500706A (ja) 2007-01-18
CA2534228A1 (en) 2005-02-10
ES2313079T3 (es) 2009-03-01
DK1660491T3 (da) 2008-11-10
PT1660491E (pt) 2008-10-10
AU2004261628B2 (en) 2011-05-12
RU2006102510A (ru) 2006-07-27
HRP20060041A2 (en) 2006-11-30
CY1108560T1 (el) 2014-04-09
BRPI0413072A (pt) 2006-10-03
RU2359970C2 (ru) 2009-06-27
NO20060771L (no) 2006-04-21
DE602004016002D1 (de) 2008-10-02
ZA200601716B (en) 2007-05-30
JP2007500703A (ja) 2007-01-18
WO2005012296A1 (en) 2005-02-10
BRPI0412345A (pt) 2006-10-03
UA87986C2 (uk) 2009-09-10
TW200523255A (en) 2005-07-16
NZ544970A (en) 2009-02-28
UA82888C2 (en) 2008-05-26
RU2373204C2 (ru) 2009-11-20
CN1860117A (zh) 2006-11-08
AR045729A1 (es) 2005-11-09
CA2534212A1 (en) 2005-02-10
CN1856490A (zh) 2006-11-01
HK1092790A1 (en) 2007-02-16
WO2005012297A9 (en) 2007-01-04
PL1660492T3 (pl) 2009-01-30
MY145080A (en) 2011-12-15
ATE405562T1 (de) 2008-09-15
AU2004261628A1 (en) 2005-02-10
SI1660491T1 (sl) 2009-02-28
NO20060823L (no) 2006-03-15
AR045730A1 (es) 2005-11-09
IL173372A (en) 2010-11-30
PT1660492E (pt) 2008-11-13
KR20060054408A (ko) 2006-05-22
RU2006102508A (ru) 2006-07-27
AU2004261610B2 (en) 2010-05-20
WO2005012297A1 (en) 2005-02-10
SI1660492T1 (sl) 2009-02-28
US20050043379A1 (en) 2005-02-24
HK1090359A1 (en) 2006-12-22
ES2311858T3 (es) 2009-02-16
PL1660491T3 (pl) 2009-01-30
KR101149379B1 (ko) 2012-06-28
TWI362383B (en) 2012-04-21
JP4726238B2 (ja) 2011-07-20

Similar Documents

Publication Publication Date Title
ATE403654T1 (de) Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren
ATE426597T1 (de) Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel
ATE514682T1 (de) 4-5-diamino-n,n-dihydro-pyrazol-3-on-derivate und deren verwendung als färbemittel für keratinfasern
ATE489369T1 (de) Pyrimidinderivate und deren verwendung als cb2- modulatoren
IS7667A (is) Nýjar bensimídazólafleiður
ATE395339T1 (de) Biphenylderivate und deren verwendung als fungizide
DE60323060D1 (de) Thiazol- und oxazolderivaten als ppar modulatoren
ATE511507T1 (de) Piperidinylcarbonylpyrrolidine und deren verwendung als melanocortinagonisten
ATE442366T1 (de) Oxazolidinonderivate und ihre verwendung als antibiotika
ATE316523T1 (de) Benzoxazinderivate als 5-ht6-modulatoren und deren verwendungen
ATE555097T1 (de) 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente
DE602005007866D1 (de) 1-phenyl- und 1-pyridylpyrazolderivate und deren verwendung als pestizide
ATE371653T1 (de) Benzoxazinderivate und deren verwendungen
DE60311277D1 (de) Benzotriazabicyclische derivate und deren verwendung als beta-lactamaseinhibitoren und antibakterielle mittel
DE602004020998D1 (de) 6-(1,1-difluoralkyl)-4-aminopicolinate und deren verwendung als herbizide
ATE372342T1 (de) Substituierte aminoisoxazolinderivate und ihre verwendung als antidepressiva
ATE456568T1 (de) Kondensierte heterocyclische isoxazolinderivate und deren verwendung als antidepressiva
DE602004028116D1 (de) Verwendung von ppar-gamma-agonisten als mittel gegen infektionen
DE60316290D1 (de) Oxazolderivat und deren verwendung als insulinsensibilisatoren
DE602005008954D1 (de) Indazol- und indolonderivative und deren verwendung als pharmazeutika
ATE366252T1 (de) Neue anilin-derivate, deren herstellung und verwendung als pharmazeutika
DE602007009978D1 (de) Neuartige 1,4-diazabicycloä3.2.2ünonan-derivate und deren medizinische verwendung
DE60323849D1 (de) Polybenzazolfaser und deren verwendung
IS8446A (is) Staðgengin bensimidasól-, benstríasól- og bensimidasólon-o-glúkósíð
ATE521632T1 (de) Metastinderivate und verwendung davon

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1660491

Country of ref document: EP

REN Ceased due to non-payment of the annual fee